New cTAP Evidence Supports Patient-Centric Alternatives

CureDuchenne was the original funder of cTAP. We congratulate the consortium and other authors on their recent publication looking at large data sources and investigating effects of different genotypes on motor function outcomes over 1 year.

Their findings indicate that other prognostic factors, such as baseline function, introduce more variability than genotype differences. This is good news for clinical trial design since the use of genotypically mixed or unmatched controls can ease recruitment challenges and reduce the number of participants assigned to placebo controls.

Read the full press release below.

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.